Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

n, of which $8.5 million was related to cost sharing and $18.1 million was related to the Excess Amounts, which are due to be received during our quarter ending March 31, 2013. At June 30, 2012, the Company had $5.8 million due from Janssen related to cost sharing. At September 30, 2012, the Company had cash, cash equivalents and marketable securities of $286.1 million.

The Company expects to end calendar year 2013 with cash, cash equivalents and marketable securities of more than $225 million.

"Ibrutinib has demonstrated great clinical progress during this past year. Today we have a very solid development program in place with 5 Phase III trials initiated and several more trials to be started this year. We were honored to announce this past Tuesday that ibrutinib received Breakthrough Designation in two B-cell malignancies. We look forward to working with the FDA to bring this therapy to market in a timely manner," said Bob Duggan, CEO and Chairman of the Board. "Looking ahead, our goals for this year are star high as we are continuing to unfold our clinical program. With our partner Janssen, we are committed to a shared vision of patient friendly, body harmonious solutions intended to improve the quality of life, increase duration of life and resolve serious medical health care needs for patients."

Recent Developments & HighlightsBreakthrough Therapy Designation

The Breakthrough Therapy Designation is intended to expedite the development and review of a potential new drug for serious or life-threatening diseases where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation of a drug as a Breakthrough Therapy was enacted as part of the 2012 Food and Drug Administration Safety and Innovation Act.

Pharmacyclics, together
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... Oct. 27, 2014 Kalorama Information says that ... concern in the United States ... healthcare market researcher said the FDA,s Emergency Use Authorization (EUA) ... tests for the detection of the Ebola virus was ... Kalorama routinely assess the IVD industry and its biennial ...
(Date:10/27/2014)... The report “Smart Highway Market by Technology (Intelligent ... by Display (Variable Message Signs, Digital Signage) - ... into various sub-segments with in-depth analysis and forecasting ... restraints for this market with insights into trends, ... and 37 figures spread through 141 pages in-depth ...
(Date:10/26/2014)... The report "Data Center Networking Market [Ethernet switches, ... Appliances]: Global Advancements, Worldwide Forecasts & Analysis (2013-2018)" ... into various segments with an in-depth analysis and ... factors driving this market, various restraints and challenges, ... roadmaps. , Browse 106 market data tables and ...
(Date:10/25/2014)... BioProcess International (BPI), a business-to-business ... BioProcess International Awards. The awards celebrate the outstanding ... technology applications that will allow the industry to ... patient base. , Winners and finalists were honored ... entertaining and exciting awards dinner and ceremony yesterday ...
Breaking Biology Technology:Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 2Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 4Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 2Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 2BioProcess International Announces Winners of the 2014 BioProcess International Awards 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 5
... 21, 2012 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: ... the development, manufacturing, and marketing of branded generic and ... report its unaudited financial results for the fourth quarter ... March 7, 2012, before the market opens in the ...
... University have developed a new method for chemically ... step toward the creation of faster, thinner, flexible ... attributes, graphene is a one-atom thick, honeycomb-shaped lattice ... Among graphene,s many possible applications is electronics: Many ...
... announced that it has held an End-of-Phase 2 meeting with ... clinical studies completed for XaraColl ® and to discuss ... Phase 3. XaraColl ® is being developed for postoperative ... in patients undergoing hernia repair. FDA agreed to the Phase ...
Cached Biology Technology:Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2011 Financial Results on Wednesday, March 7, 2012 2A step toward better electronics 2Innocoll Announces Successful End-of-Phase 2 Meeting with FDA for XaraColl® and Agreement of the Phase 3 Program 2
(Date:10/28/2014)... . , How ... when times are lean? By studying wild chimpanzees in ... the Max Planck Institute for Evolutionary Anthropology in Leipzig, ... can acquire extra energy needed to maintain large, costly ... more en route to breakfast sites containing fruits that ...
(Date:10/28/2014)... moving activity in a novel environment are linked ... to an experimental study completed at the University ... Fisheries Research Institute. The study used novel, long-term ... angling trials to analyse if behaviours predict the ... traditional and enriched hatchery rearing environments. Based ...
(Date:10/27/2014)... species of the West Antarctic Peninsula (WAP), one of ... the average annual temperature in the Antarctic Peninsula has ... Celsius during winter. , As the WAP climate ... to a warmer, sub-polar system with more rain. , ... local weather conditions and the weight of Adélie penguin ...
Breaking Biology News(10 mins):The early chimp gets the fig 2The early chimp gets the fig 3Fish 'personality' linked to vulnerability to angling 2University of Delaware study connects penguin chick weights to local weather conditions 2University of Delaware study connects penguin chick weights to local weather conditions 3
... Jeremy Smith, Governor,s Chair for Molecular Biophysics ... reveal a key trigger of GerstmannStrusslerScheinker (GSS) syndrome, ... could have far-reaching implications for the treatment of ... Parkinson,s. Smith conducted his research with ...
... BeeSpace Navigator, University of Illinois researchers have created both ... approach to searching for information. The project was ... Biology and the department of computer science. Led by ... at the U. of I., the team described the ...
... Virginia Tech in Blacksburg, Va. recently found a way ... more efficient, powerful and less expensive. Specifically, they discovered ... of water or ions, which are necessary for fuel ... Nafion, a polymer electrolyte membrane, or PEM, commonly used ...
Cached Biology News:UT scientist uncovers trigger to fatal neurodegenerative disease 2New curation tool a boon for genetic biologists 2New curation tool a boon for genetic biologists 3Stretching old material yields new results for energy- and environment-related devices 2
Anti-ADAM-12 (Meltrin Alpha); amino terminal region; rabbit host...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 25 tests...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Biology Products: